[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352564-105":59,"doc-detail-352564-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evaluation-of-rc48-adc-in-combination-with-prag-regimen-an-open-label-prospective-multicentre-study","Evaluation of RC48-ADC in Combination with PRaG Regimen - An Open-Label, Prospective, Multicentre Study","","The study evaluates the effectiveness and safety of combining the antibody-drug conjugate (ADC) disitamab vedotin (RC48) with the PRaG regimen, consisting of a PD-1 inhibitor, radiotherapy, and GM-CSF, for treating HER2-expressing advanced refractory solid tumors. It uses a prospective, single-arm, open-label multicenter design with defined dosing and radiotherapy scheduling. The primary endpoint is objective response rate (ORR), with secondary endpoints including PFS, OS, DCR, safety, and QoL.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluation-of-rc48-adc-in-combination-with-prag-regimen-an-open-label-prospective-multicentre-study/352564/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluation-of-rc48-adc-in-combination-with-prag-regimen-an-open-label-prospective-multicentre-study/352564.png","ImageObject",300,407,{"name":92,"@type":93},"Mia  ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment combination does the PRaG3.0 protocol test?","Question",{"text":112,"@type":113},"It tests disitamab vedotin (RC48) combined with the PRaG regimen, integrating a PD-1 inhibitor, radiotherapy, and GM-CSF (and IL-2 in the outlined schedule).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the primary endpoint of the study?",{"text":117,"@type":113},"The primary endpoint is objective response rate (ORR).",{"name":119,"@type":110,"acceptedAnswer":120},"How are patients selected and how is therapy delivered?",{"text":121,"@type":113},"Patients must have confirmed HER2-expressing solid tumors (IHC 3+, 2+, or 1+) that progressed after standard treatment or were intolerant. RC48 is given intravenously on day 1, followed by GM-CSF and IL-2, with radiotherapy starting on day 3 and PD-1/PD-L1 antibodies within one week after radiotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352564,1790446263,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efﬁcacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol)  \nTechnology in Cancer Research & Treatment  \nVolume 25: 1-7 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15330338261432537](DOI: 10.1177/15330338261432537)[ ](DOI: 10.1177/15330338261432537)[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nMeiling Xu, MS 1,2,3,*, Yuehong Kong, PhD 1,2,3,*, Junjun Zhang, PhD 1,2,3,*, Rongzheng Chen, MS 1,2,3, Pengfei Xing, MS 1,2,3, Xiangrong Zhao, MS 1,2,3,  \nShicheng Li, PhD 1,2,3, Yingying Xu, MS 1,2,3, Liyuan Zhang, PhD 1,2,3 , and Li Zou, MS2,4   \nAbstract  \nIntroduction: This study aims to investigate the effectiveness and safety of combining the antibody-drug conjugate (ADC) disitamab vedotin (RC48) with the established PRaG regimen (PD-1 inhibitor, Radiotherapy, and GM-CSF) for treating HER2-expressing (IHC 3+, 2+, or 1 +) advanced solid tumors. This novel PRaG3.0 regimen is hypothesized to leverage the tumor radiosensitizing and immunogenic cell death properties of ADCs to amplify the synergistic antitumor effects of radioimmunotherapy, offering a potential paradigm for pan-cancer therapy.  \nMethods: This study is a prospective, single-arm, open-label, multi-center clinical trial. Patients enrolled have conﬁrmed HER2-expressing solid tumors (IHC 3+, 2+, or 1 +) that have progressed after standard treatment or were intolerant to it. Patients received RC48 (2 mg/kg) via intravenous injection on day 1, followed by subcutaneous GM-CSF at 200 µg from days 3 to 7 and interleukin-2 (IL-2) at 2 million IU from days 8 to 12. Radiotherapy was initiated on day 3, targeting one lesion with hypofractionated radiotherapy (2-3 fractions of 5 or 8 Gy). PD-1/PD-L1 antibodies were administered within one week after completing radiotherapy. Treatment was repeated every three weeks, and if there were no target lesions, radiotherapy could be discontinued, with RC48 given for at least six cycles. After achieving a complete tumor response, maintenance therapy with PD-1/PD-L1 antibodies continued until disease progression or intolerable toxicity occurred. The primary endpoint was the objective response rate (ORR).  \nResults: The study is currently in the recruitment phase (Registration No: NCT05115500). The primary endpoint is the objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), safety, and QoL. Planned enrollment is 62 patients.  \n1 Center of PRaG therapy, The Second Afﬁliated Hospital of Soochow University, Suzhou, China  \n2Center for Cancer Diagnosis and Treatment, The Second Afﬁliated Hospital of Soochow University, Suzhou, China  \n3Laboratory for Combined Radiotherapy and Immunotherapy of Cancer, The Second Afﬁliated Hospital of Soochow University, Suzhou, China 4Department of Radiotherapy and Oncology, The Second Aﬃliated Hospital of Soochow University, Suzhou City, China  \n*Meiling Xu, Yuehong Kong, and Junjun Zhang are co-ﬁrst authors.  \nCorresponding Authors:  \nLiyuan Zhang, Center of PRaG therapy, The Second Afﬁliated Hospital of  \nSoochow University, Suzhou, China; Center for Cancer Diagnosis and Treatment, The Second Afﬁliated Hospital of Soochow University, Suzhou, China; Laboratory for Combined Radiotherapy and Immunotherapy of Cancer, The Second Afﬁliated Hospital of Soochow University, Suzhou, China.  \nEmail: [zhangliyuan126@126.com](zhangliyuan126@126.com)  \nLi Zou, Center for Cancer Diagnosis and Treatment, The Second Afﬁliated Hospital of Soochow University, Suzhou, China; Department of Radiotherapy and Oncology, The Second Aﬃliated Hospital of Soochow University, Suzhou City, China.  \nEmail: [li_zou@126.com](li_zou@126.com)  \nCreative Commons Non Commerci","cbCairusB6FNRA21","https://ap.wps.com/l/cbCairusB6FNRA21","pdf",555963,"English","# Abstract\n## Introduction\n## Methods\n## Results\n## Conclusion\n## Keywords","[{\"question\":\"What treatment combination does the PRaG3.0 protocol test?\",\"answer\":\"It tests disitamab vedotin (RC48) combined with the PRaG regimen, integrating a PD-1 inhibitor, radiotherapy, and GM-CSF (and IL-2 in the outlined schedule).\"},{\"question\":\"What is the primary endpoint of the study?\",\"answer\":\"The primary endpoint is objective response rate (ORR).\"},{\"question\":\"How are patients selected and how is therapy delivered?\",\"answer\":\"Patients must have confirmed HER2-expressing solid tumors (IHC 3+, 2+, or 1+) that progressed after standard treatment or were intolerant. RC48 is given intravenously on day 1, followed by GM-CSF and IL-2, with radiotherapy starting on day 3 and PD-1/PD-L1 antibodies within one week after radiotherapy.\"}]","Evaluation of RC48-ADC in Combination with PRaG Regimen - An Open-Label, Prospective, Multicentre Study | PDF",1790100266,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58420d08f8c4809bd82e0bca77e40a02.webp",983,1276,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/902d7d2610146ad2767fb27b3e233425.webp",982,1275,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d88366ccce14ef86ac21f7b91626258.webp",981,1273,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dddadc732c22ce1b83f558ab0ef7457c.webp",980,1272]